Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4022526 | 0.88 | OPRM1 (0.43) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4021250 | 0.87 | OPRM1 (0.48) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4019150 | 0.85 | OPRK1 (0.41) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4023073 | 0.84 | OPRM1 (0.43) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4025612 | 0.84 | CHRM3 (0.43) | CHRM3CXCR3OPRM1OPRK1OPRD1 | |
| SCHEMBL4019865 | 0.82 | OPRM1 (0.45) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4021766 | 0.82 | OPRM1 (0.51) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4017778 | 0.82 | OPRM1 (0.46) | CHRM3OPRM1OPRK1OPRD1 | |
| SCHEMBL4022510 | 0.81 | OPRM1 (0.41) | OPRM1OPRK1OPRD1 | |
| SCHEMBL4018594 | 0.81 | OPRK1 (0.41) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40838-E1 | 2-azabicyclo[3.3.1]nonane derivatives | PFIZER INC. (US) | 2009-07-07 | — | — | US | claimed |
| US-7056930-B2 | for treatment of disease states, disorders and conditions mediated by opioid receptors; for example, irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia, eating disorders | PFIZER INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | PFIZER INC. | 2004-10-14 | — | — | US | claimed |
| US-RE40838-E1 | 2-azabicyclo[3.3.1]nonane derivatives | PFIZER INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7056930-B2 | for treatment of disease states, disorders and conditions mediated by opioid receptors; for example, irritable bowel syndrome, drug addiction, including alcohol addiction, depression, anxiety, schizophrenia, eating disorders | PFIZER INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | PFIZER INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204445-A1 | 2-Azabicyclo[3.3.1]nonane derivatives | OPRD1, OPRK1, OPRM1 | CHRM3 313/4885CXCR3 1185/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.